ClinicalTrials.gg
CompletedNCT04378439Updated Oct 26, 2026

Appalachian Partnership to Reduce Disparities (Aim 2)

An interventional study of Peer Navigation and mHealth in HIV/AIDS, STI and HCV, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Prevention

How we know

Updated Oct 26, 2026Now CompletedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States — 112 open to participants now, 154 under way, 9 of them phase 3. Acquired Immunodeficiency Syndrome · United States.

Enrollment
420th of 1,291
141 · median 60
Started
2022
with 51 others
No phase
642 of 1,671
59 open now
Registered
1,415th of 1,671
by date

Among the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, this one is the 420th largest by enrollment of the 1,291 interventional ones that give a count, is one of 52 that started in 2022, is one of 642 with no phase, and was the 1,415th registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

112 of the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, or all of them as a file.
02

Study summary

By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care services among racially/ethnically diverse GBMSM and transgender women in rural Appalachia.

Study Investigators anticipate that participants in the intervention group, relative to counterparts in the delayed-intervention group, will demonstrate increased HIV, STI, and HCV testing.

Read the detailed description

This CBPR study will advance prevention science and practice through testing an innovative intervention to promote and support the use of needed HIV, STI, and HCV prevention and care services among GBMSM and transgender women; and developing priorities and recommendations to improve their health that will be disseminated to inform public health practice, research, and policy. By integrating peer navigation and mHealth strategies, the proposed study provides a unique opportunity to improve health among vulnerable, hidden, and neglected populations living in rural Appalachia. Findings from this research may inform strategies and approaches to address other health disparities in other rural populations.

03

Conditions studied

04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • reside in one of the rural Appalachian catchment counties
  • be ≥18 years of age
  • report being assigned male sex at birth and having had sex with at least 1 man in past 12 months
  • provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
141 participants (actual)

Study arms

  • Active comparator
    intervention group

    7 community health leaders; 56 social network members

    Behavioral: Peer Navigation · Behavioral: mHealth

  • Active comparator
    delayed-intervention

    7 community health leaders; 56 social network members

    Behavioral: Peer Navigation · Behavioral: mHealth

Interventions

  • BehavioralPeer Navigation

    First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services. Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention

  • BehavioralmHealth

    In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate "in-real-time" via social media about the process of participating in a syringe services program or accessing PrEP.

06

What researchers measure

Primary outcomes

  1. Number of participants who have Human Immunodeficiency Virus (HIV) testing

    Time frame: baseline

  2. Number of participants who have Sexually Transmitted Infection (STI) testing

    Time frame: baseline

  3. Number of participants who have Hepatitis C Virus (HCV) testing

    Time frame: baseline

  4. Number of participants who have HIV testing

    Time frame: immediate post-intervention (12 months post-baseline)

  5. Number of participants who have STI testing

    Time frame: immediate post-intervention (12 months post-baseline)

  6. Number of participants who have HCV testing

    Time frame: immediate post-intervention (12 months post-baseline)

  7. Number of participants who have HIV testing

    Time frame: 12-month follow-up (24 months post-baseline)

  8. Number of participants who have STI testing

    Time frame: 12-month follow-up (24 months post-baseline)

  9. Number of participants who have HCV testing

    Time frame: 12-month follow-up (24 months post-baseline)

Secondary outcomes

  1. Number of participants who use prevention--Pre-exposure prophylaxis (PrEP)

    Time frame: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).

  2. Number of participants who use prevention--syringe services

    Time frame: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).

  3. Number of participants who use HIV care services

    Measured through self-report and medical chart abstraction

    Time frame: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).

  4. Number of participants who use STI treatment services

    Measured through self-report and medical chart abstraction

    Time frame: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).

  5. Number of participants who use HCV treatment services

    Measured through self-report and medical chart abstraction

    Time frame: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).

  6. Number of participants who use gender-affirming care services

    Measured through self-report and medical chart abstraction

    Time frame: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).

07

Study locations

1 site
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in May 2026, 49 months.

Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 49 months is above that.

Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion May 2027 → May 2026 and completion May 2027 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2020
First posted
May 7, 2020
StartActual
Apr 1, 2022
Primary completionActual
May 31, 2026was May 2027
CompletionActual
May 31, 2026was May 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 6, 2026
Primary completion
May 2027→May 31, 2026 (actual)
Oct 6, 2026
Study completion
May 2027→May 31, 2026 (actual)
Oct 6, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • Editedreside in one of the rural Appalachian catchment countiesreside in one of the rural Appalachian catchment counties
Oct 6, 2026
Documents
Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Documents Informed consent form ↗ posted
  2. Oct 6, 2026
    Recruiting→Completed
    Primary completion May 2027→May 31, 2026 (now actual)
    Study completion May 2027→May 31, 2026 (now actual)
    Eligibility 1 criterion edited
    What changed in the criteria
    • Editedreside in one of the rural Appalachian catchment countiesreside in one of the rural Appalachian catchment counties
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04378439
Responsible party
Sponsor
First posted
May 7, 2020
Start date
Apr 1, 2022
Primary completion
May 31, 2026
Completion
May 31, 2026
Last update
Oct 26, 2026

Study contacts

Scott D. Rhodes, Ph.D, MPH
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion